Prediction of hepatitis C virus interferon/ribavirin therapy outcome based on viral nucleotide attributes using machine learning algorithms
Abstract Background Hepatitis C virus (HCV) causes chronic hepatitis C in 2-3% of world
population and remains one of the health threatening human viruses, worldwide. In the …
population and remains one of the health threatening human viruses, worldwide. In the …
Pharmacogenomics of drug efficacy in the interferon treatment of chronic hepatitis C using classification algorithms
W Ke, Y Hwang, E Lin - Advances and Applications in …, 2010 - Taylor & Francis
Chronic hepatitis C (CHC) patients often stop pursuing interferon-alfa and ribavirin (IFN-
alfa/RBV) treatment because of the high cost and associated adverse effects. It is highly …
alfa/RBV) treatment because of the high cost and associated adverse effects. It is highly …
Sequences in the interferon sensitivity‐determining region and core region of hepatitis C virus impact pretreatment prediction of response to PEG‐interferon plus …
M Kurosaki, N Sakamoto, M Iwasaki… - Journal of medical …, 2011 - Wiley Online Library
The aim of the present study was to clarify the significance of viral factors for pretreatment
prediction of sustained virological response to pegylated‐interferon (PEG‐IFN) plus ribavirin …
prediction of sustained virological response to pegylated‐interferon (PEG‐IFN) plus ribavirin …
A machine learning-based treatment prediction model using whole genome variants of hepatitis C virus
H Haga, H Sato, A Koseki, T Saito, K Okumoto… - PloS one, 2020 - journals.plos.org
In recent years, the development of diagnostics using artificial intelligence (AI) has been
remarkable. AI algorithms can go beyond human reasoning and build diagnostic models …
remarkable. AI algorithms can go beyond human reasoning and build diagnostic models …
Prediction of prognostic biomarkers for Interferon-based therapy to Hepatitis C Virus patients: a metaanalysis of the NS5A protein in subtypes 1a, 1b, and 3a
MM ElHefnawi, S Zada, IA El-Azab - Virology journal, 2010 - Springer
Abstract Background Hepatitis C virus (HCV) is a worldwide health problem with no vaccine
and the only approved therapy is Interferon-based plus Ribavarin. Response prediction to …
and the only approved therapy is Interferon-based plus Ribavarin. Response prediction to …
An artificial neural network approach to the drug efficacy of interferon treatments
E Lin, Y Hwang, SC Wang, ZJ Gu, EY Chen - Pharmacogenomics, 2006 - Taylor & Francis
Introduction: Interferon taken alone or in combination with ribavirin can be used for the
treatment of persons with chronic hepatitis C. It is highly desirable, both clinically and …
treatment of persons with chronic hepatitis C. It is highly desirable, both clinically and …
Evaluation of machine learning algorithms for predicting direct-acting antiviral treatment failure among patients with chronic hepatitis C infection
Despite the availability of efficacious direct-acting antiviral (DAA) therapy, the number of
people infected with hepatitis C virus (HCV) continues to rise, and HCV remains a leading …
people infected with hepatitis C virus (HCV) continues to rise, and HCV remains a leading …
Genomic determinants of hepatitis C virus antiviral therapy outcomes: toward individualized treatment
M Venegas, J Brahm, RA Villanueva - Annals of hepatology, 2012 - medigraphic.com
Hepatitis C virus (HCV) is an important global health problem with an estimated prevalence
of more than 170 million infected individuals worldwide. Currently, the standard antiviral …
of more than 170 million infected individuals worldwide. Currently, the standard antiviral …
Coordinated evolution among hepatitis C virus genomic sites is coupled to host factors and resistance to interferon
Abstract Machine-learning methods in the form of Bayesian networks (BN), linear projection
(LP) and self-organizing tree (SOT) models were used to explore association among …
(LP) and self-organizing tree (SOT) models were used to explore association among …
Relevance of baseline viral genetic heterogeneity and host factors for treatment outcome prediction in hepatitis C virus 1b-infected patients
V Saludes, E Bascuñana, E Jordana-Lluch… - PLoS …, 2013 - journals.plos.org
Background Only about 50% of patients chronically infected with HCV genotype 1 (HCV-1)
respond to treatment with pegylated interferon-alfa and ribavirin (dual therapy), and …
respond to treatment with pegylated interferon-alfa and ribavirin (dual therapy), and …